Literature DB >> 2821854

Lower respiratory tract abnormalities in rheumatoid interstitial lung disease. Potential role of neutrophils in lung injury.

J G Garcia1, H L James, S Zinkgraf, M B Perlman, B A Keogh.   

Abstract

Although the etiology of rheumatoid interstitial lung disease (RILD) remains unknown, bronchoalveolar lavage (BAL) has been useful in studying potentially pathogenic mechanisms in this disorder. Previous investigations in patients with rheumatoid arthritis (RA) and RILD revealed abnormal BAL T-lymphocyte subpopulations and a significant elevation in BAL neutrophils. Because neutrophils have been implicated as important effector cells in inflammatory disorders such as ARDS and idiopathic pulmonary fibrosis, we evaluated BAL fluid in patients with RA for neutrophil chemotactic and activating properties and for evidence of neutrophil activation. The BAL fluid from patients with RILD contained significant neutrophil chemotactic activity derived from both lipid and nonlipid components. Evidence for neutrophil stimulation in the lower respiratory tract of patients with RILD was suggested by elevations in both myeloperoxidase activity and immunologically determined levels of human neutrophil elastase in BAL fluid. Free uninhibited elastolytic activity, however, was not demonstrated, suggesting that adequate protease inhibitor levels were present to inhibit active elastase activity. In addition to elevated myeloperoxidase activity, a potential role for neutrophil-derived oxidant injury was indirectly suggested by the enhanced release of superoxide anion (O2-) from resting normal human blood neutrophils challenged with concentrated BAL fluid from patients with RA and interstitial lung disease. Significant correlations were found between physiologic parameters and the percentage of BAL neutrophils, as well as levels of neutrophil-derived mediators. For example, levels of human neutrophil elastase were strongly correlated with diminished diffusion capacity (r = -0.73, p less than 0.001) and reduced forced vital capacity (r = -0.63, p less than 0.006).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2821854     DOI: 10.1164/ajrccm/136.4.811

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  11 in total

1.  Mice lacking neutrophil elastase are resistant to bleomycin-induced pulmonary fibrosis.

Authors:  Felix Chua; Sarah E Dunsmore; Peter H Clingen; Steven E Mutsaers; Steven D Shapiro; Anthony W Segal; Jürgen Roes; Geoffrey J Laurent
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 2.  Subclinical alveolitis in immunologic systemic disorders.

Authors:  B Wallaert
Journal:  Lung       Date:  1990       Impact factor: 2.584

3.  Bronchoalveolar lavage in patients with mild and severe rheumatoid lung disease.

Authors:  D M Gilligan; C M O'Connor; K Ward; D Moloney; B Bresnihan; M X FitzGerald
Journal:  Thorax       Date:  1990-08       Impact factor: 9.139

4.  Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis.

Authors:  J Biederer; A Schnabel; C Muhle; W L Gross; M Heller; M Reuter
Journal:  Eur Radiol       Date:  2003-10-14       Impact factor: 5.315

Review 5.  New perspectives on basic mechanisms in lung disease. 6. Proteinase imbalance: its role in lung disease.

Authors:  T D Tetley
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

6.  Imaging of pulmonary disease in rheumatoid arthritis using J001X scintigraphy: preliminary results.

Authors:  P Goupille; P Diot; J P Valat; E Lemarie; C Valat; E Asquier; A Delarue; A Le Pape
Journal:  Eur J Nucl Med       Date:  1995-12

Review 7.  The multifaceted aspects of interstitial lung disease in rheumatoid arthritis.

Authors:  Lorenzo Cavagna; Sara Monti; Vittorio Grosso; Nicola Boffini; Eva Scorletti; Gloria Crepaldi; Roberto Caporali
Journal:  Biomed Res Int       Date:  2013-09-25       Impact factor: 3.411

Review 8.  Pivotal roles of GM-CSF in autoimmunity and inflammation.

Authors:  Aoi Shiomi; Takashi Usui
Journal:  Mediators Inflamm       Date:  2015-03-08       Impact factor: 4.711

Review 9.  GM-CSF as a therapeutic target in autoimmune diseases.

Authors:  Aoi Shiomi; Takashi Usui; Tsuneyo Mimori
Journal:  Inflamm Regen       Date:  2016-07-05

10.  IL-17A+GM-CSF+ Neutrophils Are the Major Infiltrating Cells in Interstitial Lung Disease in an Autoimmune Arthritis Model.

Authors:  Oh Chan Kwon; Eun-Ju Lee; Eun-Ju Chang; Jeehee Youn; Byeongzu Ghang; Seokchan Hong; Chang-Keun Lee; Bin Yoo; Yong-Gil Kim
Journal:  Front Immunol       Date:  2018-07-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.